What's new

Filters: policy
x
Newsroom

Twitter

Videos

Photos

20160128 EGA Regulatory and Scientific Affairs Conferenc

Fighting counterfeit medicines in Europe: the effect on access to medicines

14 September 2017

Policy

The implementation of the Falsified Medicines Directive, and its Delegated […]

Read more

US FDA Advisory committee hears first-hand about the decade of EU experience with biosimilar medicines use

13 July 2017

Policy

Medicines for Europe Director General Adrian van de Hoven participated […]

Read more

Medicines for Europe Country Specific Market Access Policies

23 May 2017

Policy

Open

Positioning Statements on Physician-led Switching for Biosimilar Medicines

7 March 2017

Policy

Positioning Statements on Physician-led Switching for Biosimilar Medicines BIOSIMILAR MEDICINES […]

Read more

Essential Medicines for Universal Health Coverage

7 November 2016

Policy

Open

Medicines for Europe’s Contribution to WHO’s Biological Qualifier (BQ) Developments (PRESENTATION and SPEECH)

18 October 2016

Policy

      18 October 2016 Suzette Kox Senior Director […]

Read more

Understanding the Science of Extrapolation and Defining Interchangeability – Dr. Elena Wolff-Holz, EULAR Symposium London

10 June 2016

Policy

Open

EGA-EBG Summary Position Regarding the WHO Biologic Qualifier Proposal (INN Working Doc. 14.342)

21 March 2016

Policy

Open

Biosimilar Product Labelling

2 February 2016

Policy

Open

EGA-EBG Considerations on WHO’s BQ Proposal – Suzette Kox, WHO INN Open Session with Stakeholders, Geneva, 13 October 2015 (PPT)

13 October 2015

Policy

Open

Subscribe to our newsletter